US 12,122,999 B2
Composition for preventing or treating cognitive dysfunction including inhibitor or MECP2 expression
Heh-In Im, Seoul (KR); Sangjoon Lee, Seoul (KR); and Ji Eun Choi, Seoul (KR)
Assigned to Korea Institute of Science and Technology, Seoul (KR)
Filed by KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, Seoul (KR)
Filed on May 16, 2022, as Appl. No. 17/745,416.
Claims priority of application No. 10-2021-0118530 (KR), filed on Sep. 6, 2021.
Prior Publication US 2023/0075981 A1, Mar. 9, 2023
Int. Cl. C12N 15/113 (2010.01); A61P 25/28 (2006.01)
CPC C12N 15/113 (2013.01) [A61P 25/28 (2018.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A method for treating Alzheimer's disease, comprising administering to a human or non-human mammal in need of such treatment a pharmaceutical composition comprising an inhibitor of methyl CpG binding protein 2 (MECP2) expression or activity as an active ingredient,
wherein the inhibitor of MECP2 expression or activity is shRNA that bind complementarily to the MECP2 mRNA or a viral vector containing the shRNA, and
wherein the shRNA inhibiting MECP2 expression has the sequence set forth in any one of SEQ ID NOS: 3 to 6.